We are live on ! Find out more
OPRX icon

OptimizeRx

126 hedge funds and large institutions have $274M invested in OptimizeRx in 2025 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 29 increasing their positions, 37 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more call options, than puts

Call options by funds: $3.26M | Put options by funds: $1.23M

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

73% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 22

64% more capital inflows, than outflows

Capital inflows: $39.5M | Capital outflows: $24.2M

15% more funds holding

Funds holding: 110 → 126 (+16)

4.6% more ownership

Funds ownership: 67.35% → 71.95% (+4.6%)

22% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 37

Holders
126
Holders Change
+16
Holders Change %
+14.55%
% of All Funds
1.64%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
38
Increased
29
Reduced
37
Closed
22
Calls
$3.26M
Puts
$1.23M
Net Calls
+$2.03M
Net Calls Change
+$193K

OPRX Hedge Fund Activity: Q3 2025 in Review

126 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q3 2025, worth a combined $274M — up 63% from $168M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new OPRX positions and 22 closed out — a net gain of 16 holders — while 29 added to existing stakes and 37 trimmed.

The largest buyer was CenterBook Partners, opening a new position worth an estimated $4.9M. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $2.89M.

  • 126 institutional investors held OptimizeRx (OPRX) as of Q3 2025, up from 110 in Q2 2025.
  • Funds reported $274M of OptimizeRx stock for Q3 2025, up 63% quarter-over-quarter.
  • 38 funds opened new OptimizeRx positions in Q3 2025 and 22 closed out, a net change of +16 holders.
  • The largest OptimizeRx buyer in Q3 2025 was CenterBook Partners, an estimated $4.9M added.
  • The largest OptimizeRx seller in Q3 2025 was Schonfeld Strategic Advisors, an estimated $2.89M sold.

Based on aggregated 13F filings for Q3 2025.